CoChat

Controlled clinical trial of interferon-gamma as postoperative surgical adjuvant therapy for colon cancer.

Wiesenfeld, M, O'Connell, M J, Wieand, H S, Gonchoroff, N J, Donohue, J H, Fitzgibbons, R J, Krook, J E, Mailliard, J A, Gerstner, J B, Pazdur, R · 1995 · Journal of Clinical Oncology
Cited by 64

The DOI matches its Crossref record.

Abstract

PURPOSE: The primary goal of this study was to assess the effectiveness of interferon gamma (IFN-gamma) to prevent tumor relapse following potentially curative surgery in patients with high-risk colon cancer. A secondary goal was to determine the effect of IFN-gamma on immune function and to correlate alterations in immune parameters with survival. PATIENTS AND METHODS: Three to 4 weeks after undergoing resection of all known malignant disease, 99 patients with stage II, III, or IV colon cancer were randomly assigned to receive IFN-gamma 0.2 mg total dose by subcutaneous injection daily for 6 months or observation. Serial assessment of human leukocyte antigen (HLA)-DR expression and Fc receptors on peripheral-blood monocytes was conducted in 24 patients who received IFN-gamma and 27 control patients. RESULTS: With a median follow-up duration of 59 months in patients still alive, there was evidence of a detrimental effect on time to relapse (P = .03) among patients who received IFN-gamma. There was no significant difference in patient survival (P = .12). This study has sufficient power to rule out a 25% reduction in death rate for patients who received IFN-gamma (P < .05). Significant enhancement of immune function was observed in patients treated with IFN-gamma as measured by HLA-DR expression (P < .01) and Fc receptors (P < .001) on peripheral-blood monocytes. CONCLUSION: This study effectively rules out any clinically meaningful benefit for IFN-gamma as surgical adjuvant treatment for patients with high-risk colon cancer. Although significant enhancement of nonspecific immune function was seen with this dosage administration schedule of IFN-gamma, this was not associated with any demonstrable antitumor effect.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.1995.13.9.2324

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 64

Metadata

Authors
Wiesenfeld, M., O'Connell, M. J., Wieand, H. S., Gonchoroff, N. J., Donohue, J. H., Fitzgibbons, R. J., Krook, J. E., Mailliard, J. A., Gerstner, J. B., & Pazdur, R.
Venue
Journal of Clinical Oncology
Published
1995-09
Volume
13
Issue
9
Pages
2324-2329
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W1960879525
Cited by
64
References
0
FWCI
0.74
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Controlled clinical trial of interferon-gamma as postoperative surgical adjuvant therapy for colon cancer. https://app.cochat.ai/papers/10.1200/jco.1995.13.9.2324
The paper
Wiesenfeld, M., O'Connell, M. J., Wieand, H. S., Gonchoroff, N. J., Donohue, J. H., Fitzgibbons, R. J., Krook, J. E., Mailliard, J. A., Gerstner, J. B., & Pazdur, R. (1995). Controlled clinical trial of interferon-gamma as postoperative surgical adjuvant therapy for colon cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1995.13.9.2324

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.